Changes in patient-reported outcomes (PROs) and fecal calprotectin levels in patients with inflammatory bowel disease following a three-week gastrointestinal inpatient rehabilitation

We present evidence on rehabilitation as an important treatment in people with IBD in terms of subjective disease burden and various indicators of personal well-being. Furthermore, we advise against the use of fecal calprotectin as a marker for monitoring disease activity in short-term rehabilitation settings.